Performance of the 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis (SSc) in Large, Well-defined Cohorts of SSc and Mixed Connective Tissue Disease

REFERENCES

1. 1.↵
   1. Wigley FM,
   2. Denton C

   . Scleroderma: from pathogenesis to comprehensive management. 1st ed. New York, Dordrecht, Heidelberg, London: Springer; 2012.
2. 2.↵
   1. Steen VD

   . Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35–42.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Steen V,
   2. Domsic RT,
   3. Lucas M,
   4. Fertig N,
   5. Medsger TA Jr

   A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum 2012;64:2986–94.

   OpenUrlCrossRefPubMed
4. 4.↵
   Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581–90.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. LeRoy EC,
   2. Medsger TA Jr

   Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573–6.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Van den Hoogen KD,
   2. Fransen J,
   3. Johnson SR,
   4. Baron M,
   5. Tyndall A,
   6. Matucci M,
   7. et al.

   Classification criteria for systemic sclerosis; preliminary results[abstract]. Ann Rheum Dis 2013;72 Suppl 3:59.

   OpenUrl
7. 7.↵
   1. Hoffmann-Vold AM,
   2. Molberg O,
   3. Midtvedt O,
   4. Garen T,
   5. Gran JT

   . Survival and causes of death in an unselected and complete cohort of Norwegian patients with systemic sclerosis. J Rheumatol 2013;40:1127–33.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Pope JE

   . The diagnosis and treatment of Raynaud’s phenomenon: a practical approach. Drugs 2007;67:517–25.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Goh NS,
   2. Desai SR,
   3. Veeraraghavan S,
   4. Hansell DM,
   5. Copley SJ,
   6. Maher TM,
   7. et al.

   Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177:1248–54.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Galie N,
    2. Hoeper MM,
    3. Humbert M,
    4. Torbicki A,
    5. Vachiery JL,
    6. Barbera JA,
    7. et al.

    Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493–537.

    OpenUrlFREE Full Text
11. 11.↵
    1. Gunnarsson R,
    2. Molberg O,
    3. Gilboe IM,
    4. Gran JT

    . The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients. Ann Rheum Dis 2011;70:1047–51.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Gunnarsson R,
    2. Aalokken TM,
    3. Molberg O,
    4. Lund MB,
    5. Mynarek GK,
    6. Lexberg AS,
    7. et al.

    Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis 2012;71:1966–72.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Gunnarsson R,
    2. Andreassen AK,
    3. Molberg O,
    4. Lexberg AS,
    5. Time K,
    6. Dhainaut AS,
    7. et al.

    Prevalence of pulmonary hypertension in an unselected, mixed connective tissue disease cohort: results of a nationwide, Norwegian cross-sectional multicentre study and review of current literature. Rheumatology 2013;52:1208–13.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Ortega-Hernandez OD,
    2. Shoenfeld Y

    . Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment. Best Pract Res Clin Rheumatol 2012;26:61–72.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Hoffmann-Vold AM,
    2. Midtvedt O,
    3. Molberg O,
    4. Garen T,
    5. Gran JT

    . Prevalence of systemic sclerosis in south-east Norway. Rheumatology 2012;51:1600–5.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Alhajeri H,
    2. Hudson M,
    3. Fritzler MJ,
    4. Pope JE; and
    5. Canadian Scleroderma Research Group,
    6. Baron M

    . Evaluation of the new American College of Rheumatology/European League Against Rheumatism Criteria for the classification of systemic sclerosis in the Canadian Scleroderma Research Group Cohort [abstract]. Arthritis Rheum 2013;65 Suppl 10:S772.

    OpenUrl
17. 17.↵
    1. Jordan S,
    2. Maurer B,
    3. Toniolo M,
    4. Michel B,
    5. Distler O

    . Performance of the new EULAR/ACR classification criteria for systemic sclerosis in clinical practice [abstract]. Ann Rheum Dis 2013;72 Suppl 3:60.

    OpenUrl
18. 18.↵
    1. Mayes MD,
    2. Lacey JV Jr,
    3. Beebe-Dimmer J,
    4. Gillespie BW,
    5. Cooper B,
    6. Laing TJ,
    7. et al.

    Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246–55.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Le Guern V,
    2. Mahr A,
    3. Mouthon L,
    4. Jeanneret D,
    5. Carzon M,
    6. Guillevin L

    . Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology 2004;43:1129–37.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Sharp GC,
    2. Irvin WS,
    3. Tan EM,
    4. Gould RG,
    5. Holman HR

    . Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972;52:148–59.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Prystowsky SD

    . Mixed connective tissue disease. West J Med 1980;132:288–93.

    OpenUrlPubMed